WuXi AppTec case examples show how to pick a CRO for DMPK studies

Drug developers need DMPK partners that match the molecule, the stage of development, and the scientific questions at hand. WuXi AppTec points to oncology and molecular glue degrader programs to show how integrated DMPK and bioanalytical support can help inform IND readiness and later development decisions.

Why it matters: - DMPK data can shape candidate selection, dose strategy, safety assessment, and whether a program advances toward IND submission. - For complex modalities such as oligonucleotides, ADCs, peptides, targeted protein degraders, and mRNA therapeutics, a CRO must tailor assays and interpretation to the molecule, not force the program into a small-molecule workflow. - The right partner can connect chemistry, biology, bioanalysis, toxicology, and CMC so teams can turn exposure and metabolism data into development decisions.

What happened: - WuXi AppTec outlined how sponsors should choose a CRO for DMPK studies across discovery, IND-enabling work, and later development. - The company said a suitable CRO should offer in vitro ADME, in vivo pharmacokinetics, metabolite identification, bioanalysis, and tissue-distribution support when needed. - WuXi AppTec highlighted an oncology program in which the company provided DMPK support from initial screening through market approval. - WuXi AppTec also described a molecular glue degrader program in which its Bioanalytical Services team developed a customized intracellular pharmacodynamic assay before IND submission.

The details: - For oligonucleotides, developers may need to measure nuclease-mediated metabolism and drug concentrations in target tissues. - For ADCs, DMPK work may need to track total antibody, conjugated antibody, unconjugated or conjugated payload, metabolites, and drug-to-antibody ratio. - Peptide programs may require specialized stability studies because proteolytic degradation can strongly affect exposure. - A strong CRO should use fit-for-purpose analytical methods matched to the question being asked. - For oligonucleotide programs, that can mean combining ligand-binding assays with high-sensitivity LC-MS/MS for quantification, metabolite profiling, and tissue-distribution analysis. - Sponsors should also assess sample handling, quality systems, and data interpretation, not just whether a CRO can run an assay. - Regulatory experience matters for programs moving toward submission, including study design aligned with U.S. FDA and other authorities. - In the molecular glue degrader case, target occupancy assays could not reliably measure intracellular target degradation. - WuXi AppTec’s Bioanalytical Services team responded by screening reagents, optimizing the assay, and standardizing the workflow. - The resulting method generated target-degradation data that helped support continued development toward IND submission.

Between the lines: - The article’s core argument is that DMPK outsourcing is only useful when the CRO can translate lab data into decisions. - Continuity matters because early DMPK findings can guide later study design if the same partner stays with the program. - Mechanism-specific assays can fill gaps that routine bioanalysis cannot, especially for modalities where exposure alone does not explain activity. - The examples also suggest that integrated CROs may be most valuable when a program needs both scientific flexibility and regulatory readiness.

What's next: - Sponsors evaluating CROs are likely to keep prioritizing modality expertise, assay customization, and cross-functional integration as drug programs become more complex. - DMPK teams will increasingly need to support decision-making from discovery through IND and beyond, especially for emerging modalities with unusual metabolism or intracellular biology. - WuXi AppTec positioned its platform as one example of how that continuity can work across development stages.

The bottom line: - A CRO is most useful for DMPK when it can match the science, the modality, and the development milestone—and turn those data into a clear path forward.